Zimmer Biomet Holdings Inc (NYSE:ZBH) has been assigned a consensus rating of “Buy” from the twenty-seven brokerages that are covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and nineteen have given a buy rating to the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $147.95.
A number of analysts have recently commented on ZBH shares. BTIG Research raised Zimmer Biomet from a “neutral” rating to a “buy” rating and set a $158.00 price target for the company in a research note on Monday, October 7th. ValuEngine cut Zimmer Biomet from a “buy” rating to a “hold” rating in a research note on Wednesday, August 21st. Raymond James upped their price target on Zimmer Biomet from $150.00 to $160.00 and gave the company an “outperform” rating in a research note on Wednesday, November 6th. Barclays raised Zimmer Biomet from an “underweight” rating to an “equal weight” rating and upped their price target for the company from $117.00 to $140.00 in a research note on Tuesday, July 30th. Finally, Royal Bank of Canada upped their price target on Zimmer Biomet from $145.00 to $155.00 and gave the company an “outperform” rating in a research note on Wednesday, November 6th.
In related news, insider Didier Deltort sold 360 shares of the business’s stock in a transaction that occurred on Friday, September 6th. The stock was sold at an average price of $139.25, for a total value of $50,130.00. Following the completion of the transaction, the insider now directly owns 1,194 shares in the company, valued at approximately $166,264.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Aure Bruneau sold 15,171 shares of the business’s stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $146.78, for a total value of $2,226,799.38. Insiders sold a total of 22,615 shares of company stock valued at $3,256,685 over the last quarter. 0.72% of the stock is owned by insiders.
Several institutional investors and hedge funds have recently modified their holdings of the stock. First Allied Advisory Services Inc. boosted its position in Zimmer Biomet by 5.8% during the 3rd quarter. First Allied Advisory Services Inc. now owns 4,177 shares of the medical equipment provider’s stock worth $579,000 after acquiring an additional 228 shares during the last quarter. Rational Advisors LLC boosted its position in Zimmer Biomet by 32.5% during the 3rd quarter. Rational Advisors LLC now owns 538 shares of the medical equipment provider’s stock worth $74,000 after acquiring an additional 132 shares during the last quarter. Corient Capital Partners LLC acquired a new position in Zimmer Biomet during the 3rd quarter worth approximately $303,000. Great Lakes Advisors LLC acquired a new position in Zimmer Biomet during the 3rd quarter worth approximately $2,405,000. Finally, Tamarack Advisers LP boosted its position in Zimmer Biomet by 77.8% during the 3rd quarter. Tamarack Advisers LP now owns 160,000 shares of the medical equipment provider’s stock worth $21,963,000 after acquiring an additional 70,000 shares during the last quarter. Institutional investors and hedge funds own 87.09% of the company’s stock.
NYSE:ZBH traded up $1.75 on Monday, hitting $146.78. 816,800 shares of the stock were exchanged, compared to its average volume of 950,372. The stock has a market capitalization of $29.69 billion, a price-to-earnings ratio of 19.21, a P/E/G ratio of 2.75 and a beta of 1.14. Zimmer Biomet has a 52 week low of $96.99 and a 52 week high of $147.24. The company has a debt-to-equity ratio of 0.53, a quick ratio of 0.54 and a current ratio of 1.17. The company’s 50-day moving average price is $137.49 and its 200 day moving average price is $129.31.
Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings results on Tuesday, November 5th. The medical equipment provider reported $1.77 EPS for the quarter, beating analysts’ consensus estimates of $1.75 by $0.02. The company had revenue of $1.89 billion during the quarter, compared to analysts’ expectations of $1.87 billion. Zimmer Biomet had a positive return on equity of 13.71% and a negative net margin of 1.14%. Zimmer Biomet’s revenue was up 3.0% on a year-over-year basis. During the same period in the prior year, the business posted $1.63 EPS. As a group, equities research analysts predict that Zimmer Biomet will post 7.83 earnings per share for the current year.
The firm also recently disclosed a quarterly dividend, which was paid on Thursday, October 31st. Investors of record on Monday, September 30th were given a $0.24 dividend. The ex-dividend date was Friday, September 27th. This represents a $0.96 annualized dividend and a dividend yield of 0.65%. Zimmer Biomet’s dividend payout ratio is presently 12.57%.
Zimmer Biomet Company Profile
Zimmer Biomet Holdings, Inc, together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates through four segments: Spine, less Asia Pacific; Office Based Technologies; Craniomaxillofacial and Thoracic; and Dental.
Recommended Story: Real Estate Investment Trust (REIT) ETF
Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.